articleThe American Journal of Sports MedicineJan 2, 2026Closed access

Platelet-Rich Plasma in the Treatment of Musculoskeletal Disease in 2025 and Beyond

Steadman Clinic · Steadman Philippon Research Institute

PubMed
Indexed incrossrefpubmed

Abstract

Platelet-rich plasma (PRP) is a blood-based orthobiologic used to treat a myriad of musculoskeletal conditions. While in vitro and preclinical studies on PRP have been promising, clinical results have been mixed. The heterogeneity in clinical benefits is attributable to both the complexity and variability of PRP as a biologic as well as the diversity of targeted tissues and ailments. Many variables have been proposed to affect PRP's bioactivity and clinical effects, with differing levels of evidence demonstrated for each variable. These variables can be broadly categorized as biological, technical, and abnormality-specific factors. Additionally, insufficient characterization of PRP in clinical studies has been…

No related works found for this paper.